AAT 003.

Loughborough University The Centre for Biological Engineering	Acqu	Vlaterials		
Doc Ref: FS008.1 : HTA-PR-FORM/007	Version N°:	1.0	Issue Date:	

ARF No: CBE/ARF/000 7

PART A: To be completed by the R	eceiver (a separate	e form must be o	completed for	each sample	type)		
A1. Details of Sample/Specimen							
Type/ID: (eg primary cell, cell line, tissue, fluid, excreta, biological agent)	Human Coro	Human Cord Blood (Ficolled) CD34+ isolation				⊠Human □Animal	
Format / Quantity: (eg vials, slides, etc)	4x50mL tub	4x50mL tube containing ~21mL ficol unit. 4 donors total					
Tissue site/Organ source:	Cord Blood						
Batch N°:							
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.						⊠Yes□No	
						⊠Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?						□Yes ⊠No	
Is the material licensable under the HTA? Indicate source below:					9	⊠Yes □No	
	mmercial Supplier	☐ Imported (fro	om outside Eng	gland, Wales o	or N.Ireland)		
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID		Lot N°: G221222205900, G22122220530 G221222205210, G22122220554			Assigned Unique ID (Procuro): S00275303, S00275304, S00275305		
If Yes, provide Project Ref N°:	BRA060 & B	BRA060 & BRA010					
If Yes, provide the name of the PI:	Dr Rob Thor	Dr Rob Thomas					
A2. Details of Receipt							
Date/Time of receipt	Date	10/10/2022	10/10/2022		16:00		
ID of Receiver	Name:	Jon Harriman	Jon Harriman		СВЕ		
ID of Supplier/Provider	Name:	Anthony Nolan		Country:	UK		
PART B: To be completed by the R	teceiver						
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number: BRA060 & BRA010				
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describe action taken				
Quantity received correct?		⊠Yes □No	If No, describe action taken				
Labelling correct and legible?		⊠Yes □No	If No, describe action taken				
attached to this form?	quality	•		⊠Yes □No □N/A			
	Agreements to ena material eg MTA, S	ements to enable transfer of erial eg MTA, SLA		⊠Yes □No □N/A			

to ensure traceability	Details/evidend	nce/assurance of			
			□Yes □No □N/A		
Temporary storage - Quarantine location (as applicable)	Building/Room		Received 16:00 10/11/22. Stored in HTA box in lab cold room overnight. Processed 11/10/22 (H21, JH) into 2x Mixed donor 1mL vials @4.8E6 and 1x Single Donor vial @ 1.5E6. Frozen via passive cooling in H34 -80C ULT freezer until 13/11/22 and transferred to LN2 cryo-bank.		
	Storage Unit ID		neezer until 13/11/22 and	t transferred to LNZ cryo-bank.	
	Within storage unit location ID 4Fri-HTA & Cryo-HTA				
	Date/Time of quarantine		Bank 7 Rack 5 Box A 1,2,5		
			13/11/2022 12:00		
Submitted by:	Signature:		Date: 10/11/22		
PART C: To be completed by th	e departmental Q	uality Manager			
C1. Quality Assurance Checks					
Has the sample/specimen been screened for infectious biological agents?				☐Yes □No □N/A	
Has the donor been screened for	™Yes □No □N/A				
Has the sample/specimen been	□Yes □No □N/A				
Is there evidence that the suppl or other recognised certification	□Yes □No □N/A				
For HTA licensable material, is t and use of the material under the	☑Yes □No □N/A				
Is there sufficient evidence to su	□Yes ☑No □N/A				
C2. Approval for release from q	uarantine				
Can the material be released from quarantine and transferred to designated storage area or released for processing?				☑Yes □No	
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Accept as is, but with extra controls			
		Rework or reprocess to meet the specified requirements			
		☐Test to meet specified requirements			
		☐Return to supplier/provider			
		□Disposal			
		Building/Room			
	Storage Unit ID				
If Yes, provide details of storage location (as applicable)		Within storage unit location ID		As about	
		Database Reference			
		Date/Time of transfer			
Approved by:		Signature:	alkarl	Date: 14/11/22 .	